The Divergence of Moats: Physical Infrastructure, Strategic Pivots, and Survival MechanicsGlobal Report·Jul 19 at 04:12 AMWU-7.00%NAK+213.00%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN+32.00%CRSP+445.00%
Market Signals Point to Growing Divergence in US Small-Cap SectorGlobal Report·Jul 17 at 04:12 AMYSXT-489.00%DWSN-387.00%
The tech fringes of 2026: AI lending, EV retreats, and the challengers still hanging onGlobal Report·Jul 15 at 04:14 AMILLR-250.00%EMR+121.00%
Mixed Signals from Micro Data: How U.S. Equities Are Navigating Sector DivergenceGlobal Report·Jul 14 at 06:47 AMTMDE-307.00%TDOC+763.00%
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-FreeTradingView·May 18 at 05:53 AMBCAB+90.00%CNTX+175.00%
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock NewsStockTitan·May 17 at 09:45 PMCNTX+175.00%BCAB+90.00%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Apr 27 at 04:05 PMTRVI-95.00%ADVB-175.00%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Apr 15 at 04:05 PMCDNA+181.00%VVOS+245.00%
NCAB Group Sets April 23 Date for First-Quarter 2026 Results PresentationTip Ranks·Apr 8 at 03:38 AMXBI+72.00%BBH+110.00%
NCAB Group Calls 2026 AGM With Expanded Voting Options for ShareholdersTip Ranks·Apr 7 at 10:24 AMIBBQ+94.00%LABU+250.00%
